CONy 2022 | Upcoming trends and advances in headache treatment
Dimos-Dimitrios Mitsikostas, MD, PhD, National & Kapodistrian University of Athens, Athens, Greece, comments on the recent developments in the field of headache research. Whilst the treatment landscape for migraines have vastly improved over recent years, novel discoveries are still being made. Additional pain pathways represent promising targets for migraines and data from upcoming trials will hopefully expand the current armamentarium. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.
Disclosures
Prof. Mitsikostas has received consulting, speaking fees and travel grants from Allergan, Amgen, Bayer, Biogen, Cefaly, Genesis Pharma, GlaxoSmithKline, ElectroCore, Eli Lilly, Merck-Serono, Merz, Mylan, Novartis, Roche, Sanofi- Genzyme, Specifar and Teva; Participated as principal investigator in randomised trials sponsored by Amgen, Eli-Lilly, ElectroCore, Merz, Novartis, Lundbeck, and Teva; Currently president of the Hellenic Headache Society, Co-Chairman of the Headache Scientific Panel at the European Academy of Neurology, and Co-Chairman of the Headache Section at CONy.
